The stock of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is a huge mover today! About 337,985 shares traded hands. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has risen 54.66% since April 5, 2016 and is uptrending. It has outperformed by 52.70% the S&P500.
The move comes after 9 months positive chart setup for the $3.24B company. It was reported on Nov, 8 by Barchart.com. We have $161.79 PT which if reached, will make NASDAQ:GWPH worth $1.00 billion more.
Analysts await GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to report earnings on December, 5. They expect $-1.59 earnings per share, down 87.06% or $0.74 from last year’s $-0.85 per share. After $-0.73 actual earnings per share reported by GW Pharmaceuticals PLC- ADR for the previous quarter, Wall Street now forecasts 117.81% negative EPS growth.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Ratings Coverage
Out of 8 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. GW Pharmaceuticals has been the topic of 10 analyst reports since August 13, 2015 according to StockzIntelligence Inc. Numis Securities upgraded GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) on Friday, August 26 to “Hold” rating. The rating was initiated by Cantor Fitzgerald with “Buy” on Friday, June 3. Roth Capital maintained the stock with “Buy” rating in Monday, March 14 report. As per Monday, November 30, the company rating was initiated by Roth Capital. The stock of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has “Sell” rating given on Monday, June 27 by Janney Capital. The rating was initiated by Morgan Stanley with “Overweight” on Thursday, August 13. On Monday, September 26 the stock rating was maintained by Cantor Fitzgerald with “Buy”. On Monday, November 30 the stock rating was initiated by TH Capital with “Buy”. Goldman Sachs initiated GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) on Friday, October 7 with “Buy” rating.
According to Zacks Investment Research, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.”
More important recent GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on April 27, 2013, also Marketwatch.com published article titled: “GW Pharmaceuticals PLC ADR”, Investorplace.com published: “GW Pharmaceuticals PLC- ADR Is a First-Rate Marijuana Stock (GWPH)” on September 26, 2016. More interesting news about GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) was released by: Investorplace.com and their article: “GW Pharmaceuticals PLC- ADR (GWPH) Boards the Buyout Rumor Mill” with publication date: September 07, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.